Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial

Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with heart failure with reduced ejection fraction, but additional information is needed about whether glycemic status influences the magnitude of their benefits on heart failure and renal events. METHODS: Patients with Class II–I...

Descripción completa

Detalles Bibliográficos
Autores principales: Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Khan, Muhammad Shahzeb, Marx, Nikolaus, Lam, Carolyn S.P., Schnaidt, Sven, Ofstad, Anne Pernille, Brueckmann, Martina, Jamal, Waheed, Bocchi, Edimar A., Ponikowski, Piotr, Perrone, Sergio V., Januzzi, James L., Verma, Subodh, Böhm, Michael, Ferreira, João Pedro, Pocock, Stuart J., Zannad, Faiez, Packer, Milton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834911/
https://www.ncbi.nlm.nih.gov/pubmed/33175585
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.051824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834911/
https://www.ncbi.nlm.nih.gov/pubmed/33175585
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.051824

Ejemplares similares